Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

Blood (2024) 144 (11): 1153–1167.

https://doi.org/10.1182/blood.2024024104

Published: 2024

Includes: Supplemental data

Journal Articles

CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dim CD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial

Blood (2023) 142 (Supplement 1): 6850.

https://doi.org/10.1182/blood-2023-178362

Published: 2023

Journal Articles

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

Blood (2023) 142 (Supplement 1): 2105.

https://doi.org/10.1182/blood-2023-180224

Published: 2023

Journal Articles

Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial

Blood (2022) 140 (Supplement 1): 10665–10667.

https://doi.org/10.1182/blood-2022-169089

Published: 2022

Journal Articles

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

Blood (2021) 138 (Supplement 1): 3864.

https://doi.org/10.1182/blood-2021-146646

Published: 2021

Journal Articles

Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies

Matthew J. Frigault, Yi-Bin Chen, Kathleen M.E. Gallagher, Nora K. Horick, Areej El-Jawahri, Irene Scarfò, Marc Wehrli, Lu Huang, Keagan Casey, Daniella Cook, Thomas Spitzer, Steven McAfee, Frederic I. Preffer, Myriam Armant, Kit L. Shaw, Heather Daley, Sarah Nikiforow, Jerome Ritz, Marcela V. Maus

Blood (2021) 138 (Supplement 1): 653.

https://doi.org/10.1182/blood-2021-146236

Published: 2021

Journal Articles

Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma

Matthew J Frigault, MD MSc, Michael R. Bishop, MD, Elizabeth K. O'Donnell, MD, Noopur S. Raje, MD, Allegra Mondillo, Daniella Cook, Heather Daley, Carissa Mangus, David W LeFleur, Janine M Buonato, Justin P Edwards, Laura K Richman, DVM, PhD, Maria T Polianova, PhD, Maria Sabatino, MD, Scott Currence, Angela Shen, MD, Travis Quigley, MS, Marcela V. Maus, MD PhD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-142931

Published: 2020

Journal Articles

Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial

Roman M Shapiro, MD, Sarah Nikiforow, MD PhD, Benedetta Rambaldi, MD, Juliana Vergara, Heather Daley, Haesook T. Kim, PhD, Corey Cutler, MD MPH, FRCPC, Vincent T. Ho, MD, John Koreth, MBBS, DPhil, Mahasweta Gooptu, MD, Joseph H. Antin, MD, Jennifer Brock, Catherine J. Wu, MD, Robert J. Soiffer, MD, Jerome Ritz, MD, Rizwan Romee, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-133933

Published: 2020

Journal Articles

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Erica B. Esrick, MD, Maureen Achebe, MD MPH, Myriam Armant, PhD, Pablo Bartolucci, MD PhD, Marioara Felicia Ciuculescu, MD, Heather Daley, Colleen Dansereau, MSN, RN, CPN, Giuseppe Di Caprio, PhD, Bronner Goncalves, MD PhD, Nicolas Hebert, Matthew M Heeney, MD, John M. Higgins, MD PhD, Leslie E. Lehmann, MD, John P Manis, MD, Olivier Negre, PhD, Sarah Nikiforow, MD PhD, Ethan Schonbrun, PhD, David K. Wood, PhD, David A. Williams, MD

Blood (2019) 134 (Supplement_2): LBA-5.

https://doi.org/10.1182/blood-2019-132745

Published: 2019

Journal Articles

Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients

Blood (2018) 132 (Supplement 1): 1023.

https://doi.org/10.1182/blood-2018-99-116733

Published: 2018

Journal Articles

Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease

Blood (2017) 130 (Supplement 1): 511.

https://doi.org/10.1182/blood.V130.Suppl_1.511.511

Published: 2017

Journal Articles

Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

Blood (2016) 128 (22): 4052.

https://doi.org/10.1182/blood.V128.22.4052.4052

Published: 2016

Journal Articles

Immune Reconstitution and Preliminary Safety Analysis Of 9 Patients Treated With Somatic Gene Therapy For X-Linked Severe Combined Immunodeficiency (SCID-X1) With a Self-Inactivating Gammaretroviral Vector

Blood (2013) 122 (21): 715.

https://doi.org/10.1182/blood.V122.21.715.715

Published: 2013

Journal Articles

Establishing CD8 + T Cell Immunity by Adoptive Transfer of Autologous, IL-15 Expanded, Anti-Tumor CTL with a Central/Effector Memory Phenotype Can Induce Objective Clinical Responses.

Marcus Butler, Philip Friedlander, Mary Mooney, Linda Drury, Martha Metzler, Matthew Milstein, Alla Berezovskaya, Marisa Flavin, Osamu Imataki, Makito Tanaka, Heather Daley, F. Stephen Hodi, Lee Nadler, Naoto Hirano

Blood (2009) 114 (22): 782.

https://doi.org/10.1182/blood.V114.22.782.782

Published: 2009

NARROW

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dim CD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial

Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform

Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies

Phase 1 Study of CART-Ddbcma, a CAR-T Therapy Utilizing a Novel Synthetic Binding Domain for the Treatment of Subjects with Relapsed and Refractory Multiple Myeloma

Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Flipping the Switch: Initial Results of Genetic Targeting of the Fetal to Adult Globin Switch in Sickle Cell Patients

Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease

Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma

Immune Reconstitution and Preliminary Safety Analysis Of 9 Patients Treated With Somatic Gene Therapy For X-Linked Severe Combined Immunodeficiency (SCID-X1) With a Self-Inactivating Gammaretroviral Vector

Establishing CD8 + T Cell Immunity by Adoptive Transfer of Autologous, IL-15 Expanded, Anti-Tumor CTL with a Central/Effector Memory Phenotype Can Induce Objective Clinical Responses.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only